|
1
|
Pogribny IP: MicroRNA dysregulation during
chemical carcinogenesis. Epigenomics. 1:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takai D: Recent proceedings in epigenetics
research of lung cancer. Nihon Rinsho. 67:2387–2396. 2009.(In
Japanese).
|
|
3
|
Wang Q, Wang S, Wang H, Li P and Ma Z:
MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction
and treatment. Exp Biol Med. 237:227–235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang J, Lee SY, Lee SY, et al:
microRNA-99b acts as a tumor suppressor in non-small cell lung
cancer by directly targeting fibroblast growth factor receptor 3.
Exp Ther Med. 3:149–153. 2012.PubMed/NCBI
|
|
5
|
Darido C, Georgy SR, Wilanowski T, et al:
Targeting of the tumor suppressor GRHL3 by a miR-21-dependent
proto-oncogenic network results in PTEN loss and tumorigenesis.
Cancer Cell. 20:635–648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu Y, Govindan R, Wang L, et al: MicroRNA
profiling and prediction of recurrence/relapse-free survival in
stage I lung cancer. Carcinogenesis. 33:1046–1054. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Z, Zeng H, Guo Y, et al: miRNA-145
inhibits non-small cell lung cancer cell proliferation by targeting
c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gregersen LH, Jacobsen AB, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-145 targets YES and
STAT1 in colon cancer cells. PLoS One. 5:e88362010.
View Article : Google Scholar
|
|
9
|
Dhomen NS, Mariadason J, Tebbutt N and
Scott AM: Therapeutic targeting of the epidermal growth factor
receptor in human cancer. Crit Rev Oncog. 17:31–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ayoola A, Barochia A, Belani K and Belani
CP: Primary and acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small cell lung cancer:
an update. Cancer Invest. 30:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Wang X, Zhang J, et al: MicroRNAs
involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol.
106:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmidt-Ullrich RK, Mikkelsen RB, Dent P,
et al: Radiation-induced proliferation of the human A431 squamous
carcinoma cells is dependent on EGFR tyrosine phosphorylation.
Oncogene. 15:1191–1197. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ellis AG, Doherty MM, Walker F, et al:
Preclinical analysis of the analinoquinazoline AG1478, a specific
small molecule inhibitor of EGF receptor tyrosine kinase. Biochem
Pharmacol. 71:1422–1434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burke WM, Jin X, Lin HJ, et al: Inhibition
of constitutively active Stat3 suppresses growth of human ovarian
and breast cancer cells. Oncogene. 20:7925–7934. 2001. View Article : Google Scholar
|
|
16
|
Pene F, Claessens YE, Muller O, et al:
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase
pathways in the proliferation and apoptosis in multiple myeloma.
Oncogene. 21:6587–6597. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Satoh T, Nakatsuka D, Watanabe Y, Nagata
I, Kikuchi H and Namura S: Neuroprotection by MAPK/ERK kinase
inhibition with U0126 against oxidative stress in a mouse neuronal
cell line and rat primary cultured cortical neurons. Neurosci Lett.
288:163–166. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seo IA, Lee HK, Shin YK, et al: Janus
kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by
suppressing protein translation of gp130. Korean J Physiol
Pharmacol. 13:131–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Walker EH, Pacold ME, Perisic O, et al:
Structural determinants of phosphoinositide 3-kinase inhibition by
wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol
Cell. 6:909–919. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Favata MF, Horiuchi KY, Manos EJ, et al:
Identification of a novel inhibitor of mitogen-activated protein
kinase kinase. J Biol Chem. 273:18623–18632. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sebolt-Leopold JS and Herrera R: Targeting
the mitogen-activated protein kinase cascade to treat cancer. Nat
Rev Cancer. 4:937–947. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sachdeva M, Zhu S, Wu F, et al: p53
represses c-Myc through induction of the tumor suppressor
miR-145. Proc Natl Acad Sci USA. 106:3207–3212. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takaoka Y, Shimizu Y, Hasegawa H, et al:
Forced expression of miR-143 represses ERK5/c-Myc and p68/p72
signaling in concert with miR-145 in gut tumors of
ApcMin Mice. PLoS One. 7:e421372012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou CH, Yang SF and Li PQ: Human lung
cancer cell line SPC-A1 contains cells with characteristics of
cancer stem cells. Neoplasma. 59:685–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Z, Zhang X, Yang Z, et al: MiR-145
regulates PAK4 via the MAPK pathway and exhibits an antitumor
effect in human colon cells. Biochem Biophys Res Commun.
427:444–449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gotte M, Mohr C, Koo CY, et al:
miR-145-dependent targeting of junctional adhesion molecule A and
modulation of fascin expression are associated with reduced breast
cancer cell motility and invasiveness. Oncogene. 29:6569–6580.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eck MJ and Yun CH: Structural and
mechanistic underpinnings of the differential drug sensitivity of
EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta.
1804:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mukohara T, Kudoh S, Yamauchi S, et al:
Expression of epidermal growth factor receptor (EGFR) and
downstream-activated peptides in surgically excised non-small-cell
lung cancer (NSCLC). Lung Cancer. 41:123–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koivunen JP, Mermel C, Zejnullahu K, et
al: EML4-ALK fusion gene and efficacy of an ALK kinase
inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283. 2008.
View Article : Google Scholar
|
|
30
|
Chen H, Kovar J, Sissons S, et al: A
cell-based immunocytochemical assay for monitoring kinase signaling
pathways and drug efficacy. Anal Biochem. 338:136–142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
